Breast Cancer Clinical Trial
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Summary
This study will evaluate the local control rate, cosmetic results, and complication rates of breast brachytherapy delivered using the MammoSite-ML® when used as the sole method of radiation therapy or as a boost technique for patients with stage I-II carcinoma of the breast (< 3 cm), (non-lobular histology) treated with lumpectomy with histologically negative surgical margins by at least 2 mm, negative axillary lymph nodes, and DCIS.
Hypotheses:
For selected patients with stage I breast carcinoma and Ductal Carcinoma In Situ (DCIS), radiation therapy delivered with brachytherapy alone using the MammoSite-ML® is technically feasible and reproducible with acceptable complication rates.
Cosmetic results after brachytherapy will be similar to that obtained after traditional whole breast external beam radiation therapy.
Local tumor control rate in the breast after brachytherapy will be similar to that of conventional external beam radiation therapy, with less inconvenience and potentially less cost to the patient, given the selection criteria which minimize the risk of clinically significant multicentric or extensive residual carcinoma following lumpectomy.
Eligibility Criteria
Inclusion Criteria:
Women,age of at least 45 years
Zubrod performance status of 0-2
AJCC Stage I-II (T1-T2, N0 M0) breast cancer
Maximum tumor dimension < 3 cm
Invasive ductal, medullary, papillary, tubular, colloid (mucinous) histologies
Unifocal breast cancer
Unilateral breast cancer (no synchronous or previous contralateral breast cancer)
Lumpectomy with negative surgical margins by at least 2 mm or re-excision specimen with negative surgical margins by at least 2 mm
Ductal Carcinoma In-Situ
Negative axillary lymph nodes for invasive breast cancer (sentinel node biopsy or standard level I-II dissection with > 6 nodes removed)
Time interval from final breast surgery to brachytherapy loading less than 8 weeks
At least 2 mm of breast tissue between the skin and the MammoSite® balloon surface(prefer > 5 mm)
If chemotherapy is planned, it must begin no earlier that 2 weeks following completion of radiation therapy. If chemotherapy is first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation therapy.
Signed study-specific consent form
Exclusion Criteria:
Invasive lobular histology
Non-epithelial breast malignancies such as sarcoma or lymphoma
Multifocal or multicentric invasive carcinoma
Extensive intraductal component (EIC)
Paget's disease of the nipple
Skin involvement by tumor, regardless of tumor size
Positive axillary lymph nodes
Distant metastases
Collagen vascular disease (scleroderma)
Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females (negative pregnancy test for women of child-bearing age)
Any previously treated or synchronous contralateral breast carcinoma
Patients with psychiatric or addictive disorder that would preclude obtaining informed Consent
Men
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Saint Louis Missouri, 63011, United States
Saint Louis Missouri, 63141, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.